|Mr. Robert Farrell J.D.||CEO, Pres & Director||353k||N/A||N/A|
|Ms. Victoria Diana Rudman||Interim CFO, Treasurer & Sec.||53k||N/A||1968|
|Mr. Seth Yakatan||Co-Founder||N/A||N/A||1970|
|Dr. Stuart L. Silverman M.D., FACP, FACR||Co-Chair of Scientific Advisory Board and VP of Medical Affairs||N/A||N/A||1947|
|Dr. Sari Prutchi-Sagiv Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Kalytera Therapeutics, Inc. a clinical-stage specialty pharmaceutical company, develops cannabidiol medicines for the treatment of serious and life threatening human diseases. The company is developing cannabidiol formulations to prevent and treat acute graft versus host diseases. The company is also developing K-1032, a prodrug for the treatment of chronic inflammatory skin diseases, such as acne vulgaris; K-1012, a prodrug for the treatment of adult respiratory distress syndrome; K-1022, a prodrug to treat ulcerative colitis; and K-1052, a prodrug for the treatment of sepsis-induced acute renal failure and traumatic brain injury. Kalytera Therapeutics, Inc. was founded in 2014 and is headquartered in San Rafael, California.
Kalytera Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.